Associated tags: Patient, PTC, PTC Therapeutics, Therapy, Pharmaceutical industry
Locations: BELGIUM, UNITED STATES, BOSTON, MA, EUROPE, NEW JERSEY, SG, EU, US
WARREN, N.J., May 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
Key Points:
- WARREN, N.J., May 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
- It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.
SOUTH PLAINFIELD, N.J., April 11, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25, at 4:30 p.m.
Key Points:
- SOUTH PLAINFIELD, N.J., April 11, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25, at 4:30 p.m.
- To access the call by phone, please click here to register and you will be provided with dial-in details.
- To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
- The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .
PTC Therapeutics,
MAA,
Ataluren,
Patient,
PKU,
NDA,
EMA,
Eladocagene exuparvovec,
Duchenne muscular dystrophy,
Therapy,
PTC,
FDA,
AADC,
BLA,
Pharmaceutical industry SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. In addition, based on recent feedback from the FDA, PTC plans to re-submit an NDA for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC expects to make the NDA resubmission by mid-year.
Key Points:
- SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.
- In addition, based on recent feedback from the FDA, PTC plans to re-submit an NDA for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
- PTC expects to make the NDA resubmission by mid-year.
- The data collected to date continue to demonstrate the transformative clinical benefits the gene therapy provides to patients," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics.
Retrieved on:
Tuesday, February 27, 2024
SOUTH PLAINFIELD, N.J., Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
Key Points:
- SOUTH PLAINFIELD, N.J., Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
- It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.
Retrieved on:
Thursday, February 15, 2024
SOUTH PLAINFIELD, N.J., Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29, at 4:30 p.m. EST.
Key Points:
- SOUTH PLAINFIELD, N.J., Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29, at 4:30 p.m. EST.
- To access the call by phone, please click here to register and you will be provided with dial-in details.
- To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
- The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors.
Key Points:
- SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors.
- The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
- What if I purchased PTC securities?
- If you purchased securities and suffered significant losses on your investment, join our investigation now:
There is no cost or obligation to you.
Nikolaus Friedreich,
Regulation,
Conference,
Eladocagene exuparvovec,
Economics,
PTC,
EMA,
FDA,
MAA,
Friedreich's ataxia,
Duchenne muscular dystrophy,
FA,
NDA,
Deflazacort,
Prescription,
HD,
Civil service commission,
Therapy,
Bank statement,
PTC Therapeutics,
Cardinal,
DMD,
PKU,
European,
Duchenne,
AADC,
Patient,
ALS,
GAAP,
CHMP,
BLA,
Pharmaceutical industry SOUTH PLAINFIELD, N.J., Jan. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P. Morgan Healthcare Conference today, Monday, January 8, at 10:30am EST/7:30am PST. Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics, will provide an update on 2023 accomplishments and highlight potential 2024 value-creating milestones. Preliminary 2023 unaudited financial results and 2024 financial guidance will also be provided. The presentation is being webcast live on the Events and Presentations page of the Investors section of PTC Therapeutics website at www.ptcbio.com.
Key Points:
- Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics, will provide an update on 2023 accomplishments and highlight potential 2024 value-creating milestones.
- The presentation is being webcast live on the Events and Presentations page of the Investors section of PTC Therapeutics website at www.ptcbio.com .
- PTC announced strategic portfolio prioritizations, which resulted in reductions in both operating expenses and headcount of approximately 25% and 30%, respectively.
- PTC maintains all economics associated with up to $250 million in the remaining commercial sales milestones associated with Evrysdi global net sales.
Retrieved on:
Tuesday, December 5, 2023
NDA,
STRIDE,
Food,
Therapy,
PTC Therapeutics,
European Commission,
Type,
Disease,
PTC,
Civil service commission,
Patient,
FDA,
CHMP,
Committee,
File,
Ataluren SOUTH PLAINFIELD, N.J., Dec. 5, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States.
Key Points:
- SOUTH PLAINFIELD, N.J., Dec. 5, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States.
- The re-examination procedure will focus only on the renewal of the existing conditional marketing authorization.
- "PTC continues to work to secure global registrations that will enable access to Translarna for patients with nmDMD worldwide," said Matthew B. Klein, M.D., Chief Executive Officer of PTC.
- In the U.S., we look forward to continuing to work collaboratively with FDA on the contents of a potential NDA resubmission."
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
SOUTH PLAINFIELD, N.J., Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Oct. 26, at 4:30 p.m.
Key Points:
- SOUTH PLAINFIELD, N.J., Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Oct. 26, at 4:30 p.m.
- To access the call by phone, please click here to register and you will be provided with dial-in details.
- To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
- The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .
